XLV - Health Care Select Sector SPDR ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
89.02
+0.78 (+0.88%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close88.24
Open88.00
Bid87.71 x 800
Ask88.49 x 3000
Day's Range87.93 - 89.39
52 Week Range78.74 - 96.06
Volume8,731,630
Avg. Volume13,241,814
Net Assets17.98B
NAV86.43
PE Ratio (TTM)N/A
Yield1.58%
YTD Return6.28%
Beta (3Y Monthly)1.01
Expense Ratio (net)0.13%
Inception Date1998-12-16
Trade prices are not sourced from all markets
  • MarketWatch22 hours ago

    Becton Dickinson profit, revenue to rise above expectations

    Becton Dickinson & Co. said it expects to swing to fiscal first-quarter net earnings per share of $2.05, from a loss of 76 cents in the same period a year ago. Excluding non-recurring items, adjusted EPS is expected to rise to $2.70 from $2.48, above the FactSet consensus of $2.59. Revenue is expected to rise 35% to $4.16 billion, topping the FactSet consensus of $4.11 billion. The medical technology company affirmed its 2019 revenue growth outlook of 8.5% to 9.5%, and its adjusted EPS guidance of $12.05 to $12.15. The stock, which was still inactive in premarket trade, has lost 5.6% over the past three months, while the SPDR Health Care Select Sector ETF has declined 5.5% and the S&P 500 has given up 6.9%.

  • UnitedHealth Pops on Solid Q4: Healthcare ETFs to Buy
    Zacks2 days ago

    UnitedHealth Pops on Solid Q4: Healthcare ETFs to Buy

    ETFs having the largest allocation to UnitedHealth has been in focus post its solid result.

  • Analysts’ Recommendations for AbbVie in January
    Market Realist4 days ago

    Analysts’ Recommendations for AbbVie in January

    Merck & Co. or AbbVie: Which Is Performing Better This Month? On January 10, AbbVie’s market cap was $132.91 billion. Based on its closing price on January 10, the company had reported returns of 2.21% in the last week, 0.67% in the last month, and -6.74% in the last quarter.

  • Top-Ranked Sector ETFs & Stocks to Buy for 2019
    Zacks8 days ago

    Top-Ranked Sector ETFs & Stocks to Buy for 2019

    Investors could be well served by ETFs and stocks from top-ranked sectors.

  • What Analysts Are Recommending for Teva Pharmaceutical in January
    Market Realist9 days ago

    What Analysts Are Recommending for Teva Pharmaceutical in January

    Teva or Mylan: Which Is the Better Generic Play in January? ## TEVA’s price movements Teva Pharmaceutical (TEVA) is a leading global pharmaceutical company with a market cap of $17.21 billion as of January 8. On the day, the company closed at $17.68 on the NYSE, up 0.06% from its previous closing price. On January 2, Teva Pharmaceutical issued a press release announcing the settlement of an ongoing patent infringement litigation with Amgen (AMGN) related to the latter’s secondary hyperparathyroidism drug, Sensipar. Based on its closing price on January 8, the company had reported returns of 14.66% in the last week, -12.73% in the last month, and -17.77% in the last quarter. Teva Pharmaceutical had also reported returns of -27.09% in the last half year, -8.01% in the last year, and 14.66% YTD (year-to-date). Based on its closing price on January 8, the broader healthcare sector represented by the Health Care Select Sector SPDR ETF (XLV) had reported returns of 0.52% in the last week, -6.42% in the last month, and -7.77% in the last quarter. XLV had also reported returns of 0.37% in the last half year, 2.01% in the last year, and 0.52% YTD. ## Analysts’ recommendations and target prices for Teva The 12-month consensus analyst recommendation for Teva Pharmaceutical as of January 9 is a “hold.” The 12-month consensus target price for the company is $22.71, 28.45% higher than its closing price on January 8. The highest target price estimate for the company is $30, and the lowest target price estimate is $15. Of the 23 analysts covering Teva Pharmaceutical on January 9, two analysts have rated the company as a “strong buy,” three have rated it as a “buy,” 15 have rated it as a “hold,” and three have rated it as a “sell.” In the next article, we’ll discuss analysts’ recommendations for Mylan in greater detail. Continue to Next Part Browse this series on Market Realist: * Part 2 - What Are Analysts Recommending for Mylan in January? * Part 3 - Teva or Mylan: Who Has the More Promising Revenue Trajectory? * Part 4 - Teva or Mylan: Whose Earnings Are Growing Faster?

  • MarketWatch9 days ago

    Illumina sees Q4 revenue above expectations, provides a mixed outlook

    Illumina Inc. provided Wednesday a fourth-quarter revenue estimate that was above expectations, and provided a mixed outlook for 2019. The stock was still inactive in premarket trade. The genetics analysis company's Chief Executive Francis deSouza said at the J.P. Morgan Healthcare Conference that fourth-quarter revenue rose 11% from a year ago to $865 million, which was above the FactSet consensus of $862 million, while full-year revenue rose 21% to $3.3 billion. For 2019, deSouza said revenue growth is expected to be 13% to 14%, while the current FactSet consensus of $3.81 billion is about 15% above 2018 revenue of $3.3 billion. The company expects 2019 adjusted earnings per share, which excludes non-recurring items, of $6.50 to $6.60, compared with the current FactSet consensus of $6.44. Illumina's stock has lost 9.3% over the past three months, while the SPDR Health Care Select Sector ETF has declined 7.9% and the S&P 500 has shed 10.6%.

  • Three Healthcare Stocks Rallying Over 10% Today
    Market Realist11 days ago

    Three Healthcare Stocks Rallying Over 10% Today

    Three Healthcare Stocks Rallying Over 10% Today ## Three healthcare stocks The broader market is trading in the green territory today but largely on a mixed note compared to the volatility in the previous couple of sessions. At 11:40 AM ET, the S&P 500 Index (SPY), NASDAQ Composite Index (QQQ), and Dow Jones Industrial Average were trading with 0.8%, 1.1%, and 0.6% gains. However, some healthcare stocks (XLV)(VHT)(IBB) were making huge moves today. Let’s take a look. ## Loxo Oncology Today before the market opened, the American pharmaceutical giant Eli Lilly and Company (LLY) announced the acquisition of Loxo Oncology (LOXO). According to the agreement between the two companies, Eli Lilly will acquire Loxo for $235.00 per share in cash, which translates into approximately $8.0 billion. After the news came out, Loxo stock surged nearly 66.0% to $232.12. ## Sage Therapeutics The biopharmaceutical firm Sage Therapeutics (SAGE) revealed positive results of the Phase 3 ROBIN Study today. The outcome of the study suggested a “significant improvement” in women with postpartum depression (or PPD) who were treated with its SAGE-217 drug for two weeks. This news boosted investors’ confidence, and SAGE stock surged 62.1% to a day high of $158.09. ## Exact Sciences The molecular diagnostics firm Exact Sciences (EXAS) said today that it expects its fourth quarter of 2018 revenue between $142.5 million and $143.5 million, which reflected about a 64% rise in its revenue from the fourth quarter of the previous year. In a press release, the company said that it “completed approximately 292,000 Cologuard tests during the fourth quarter of 2018,” up about 66% year-over-year. Plus, Exact Sciences noted, “Nearly 15,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2018.” These positive developments drove EXAS stock to rally today to post a day high of $72.78, up 11.0% from its previous session’s closing price. Note that in 2018, LOXO, LLY, and EXAS rose 66.4%, 37.0%, and 20.1%, respectively, while SAGE fell 41.8%.

  • MarketWatch11 days ago

    Hologic's stock surges after revenue outlook beats expectations

    Shares of Hologic Inc. ran up 4.7% in premarket trade Monday, after the medical technology company provided a fiscal first-quarter revenue outlook that was above expectations. The company said it expects revenue for the quarter ended Dec. 29 of $831 million, up 55 from a year ago, and above the FactSet consensus of $812 million. Among its largest business segments, the company expects breast health revenue to rise to $325 million from $288 million, above the FactSet consensus of $305 million, and expects diagnostics revenue to grow to $297 million from $285 million, better than expectations of $290 million. The company is expected to report full results in early February. The stock has slipped 3.3% over the past three months, while the SPDR Health Care Select Sector ETF has lost 8.8% and the S&P 500 has declined 12.3%.

  • MarketWatch11 days ago

    Lilly to buy Loxo Oncology in a $8 billion deal, for a 68% premium

    Shares of Loxo Onocology Inc. were indicated up about 33% in premarket trade Monday, after the biopharmaceutical company agreed to be acquired by Eli Lilly & Co. in a deal valued at $8.0 billion. Lilly's stock fell 2.7% in ahead of the open. Under terms of the deal, Lilly will pay $235 in cash for each Loxo share outstanding, which represents a 68% premium to Friday's closing price of $139.87, and 24% above Loxo's record close of $189.96 on July 6, 2018. The deal is the largest in a series of acquisitions by Lilly to broaden its cancer treatment efforts, Lilly said. The deal is expected to close by the end of the first quarter. The company said it will provide an update to 2019 financial guidance, when it reports fourth-quarter results on Feb. 13. Loxo shares have lost 12.4% over the past three months and Lilly shares have eased 0.3%, while the SPDR Health Care Select Sector ETF has shed 8.8% and the S&P 500 has declined 12.3%.

  • ETF Trends13 days ago

    Some Value Remains With HealthCare ETFs

    Compared to other sectors, healthcare was sturdy in 2018 and while the sector looks close to being fairly valued, the group could offer more upside this year. The Health Care Select Sector SPDR ETF (XLV) , the largest healthcare ETF by assets, gained 6.30% last year. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks.

  • ETF Trends14 days ago

    Healthcare ETFs Could Lead Again in 2019

    Healthcare, the second-largest sector weight in the S&P 500, was the best-performing sector in the U.S. last year. The Health Care Select Sector SPDR ETF (XLV) , the largest healthcare ETF by assets, gained 6.30% last year and some analysts believe more upside is in store for the healthcare sector in 2019. Consequently, investors may also turn to defensive sectors that are less economically sensitive, such as health care.

  • Why 'slow growth' in stocks doesn't mean 'no growth'
    Yahoo Finance Video13 hours ago

    Why 'slow growth' in stocks doesn't mean 'no growth'

    Ron Weiner of RDM Financial Group talks to Yahoo Finance's Julie Hyman and Adam Shapiro about where he sees growth in stocks right now.

  • New highs are coming this year, says Canaccord Genuity
    CNBC Videos10 days ago

    New highs are coming this year, says Canaccord Genuity

    Tony Dwyer, Canaccord Genuity, says new highs are coming this year. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Steve Grasso and Guy Adami.